Safety profiling in drug discovery
Supporting more comprehensive safety profiling decision making
It takes a huge amount of time (estimated 10-15 years) and money (estimated US$2.6 billion) to bring one drug candidate to market following its discovery. There is also a low success rate – only 0.02% of drugs in development make it to market. Given the low success rate, if drug candidates are going to fail, they need to fail fast and fail cheaply. We are passionate about supporting safety assessors in making complex decisions by working with our members to accelerate the drug development process.
It is widely reported that toxicology is the biggest driver of compound attrition during drug discovery. We can support your toxicology safety assessments – by helping you to generate enhanced safety profiles and supporting your decision making using our representation of relevant knowledge – within our in silico software solutions; Kaptis, Effiris and Derek Nexus.
Explore relevant knowledge, assay data and predictions
Our Kaptis AOP knowledge framework – which has been created, curated and peer reviewed by expert Lhasa scientists – can help you to explore relevant knowledge, assay data and predictions.
Understand the toxicological liabilities of your lead compounds
Combine existing knowledge and your own assay data in a meaningful way, using adverse outcome pathways (AOPs) within Kaptis. This integrated approach to testing and assessment (IATA) can help you to quickly understand the toxicological liabilities of your lead compound.
Improve the efficiency of your early testing strategy
Kaptis helps you to answer the question; “What should I do next?” – more specifically, which assay to run next and which adverse outcome (AO) to be concerned about. Resulting in more informed, faster, and more cost-effective human safety assessment decisions.
Effiris is a software solution which can help you to identify your promising drug candidates faster, through improved secondary pharmacology virtual screening.
Learn from other organisations’ private data
Benefit from a federated learning methodology, FLuID (Federated Learning using Information Distillation), in which each model learns from the private data of all pharmaceutical collaborators, while preserving all confidential aspects of the compounds used. As a result, overcome one of the main challenges facing model development in drug discovery – accessing and utilising high-quality proprietary data.
Improve your compound prioritisation and the efficiency of your downstream testing strategy
Make more informed decisions on which compounds to prioritise for development and rationalise observed adverse drug reactions using in silico predictions. Integrate federated Effiris models into your workflow, which will improve the efficiency of your downstream testing strategy.
Connect with industry experts
The Effiris consortium provides an opportunity to connect with other industry experts in creating improved secondary pharmacology virtual screening.
Derek Nexus is an expert, knowledge-based prediction software that can help you to profile your compounds against key toxicity endpoints using expert-derived toxicophores, based on both public and proprietary data.
Derek Nexus highlights
Triage your compound library
Identify toxicophores highlighting possible hazard quickly, through expert-curated structure-activity relationships (SARs) in your virtual screens.
Access expert-curated scientific knowledge
Utilise the scientific knowledge within Derek Nexus which is derived from both public and proprietary member data sources. We update Derek Nexus as new data becomes available.
Build confident assessments
Use the transparent predictions, knowledge and supporting evidence in Derek Nexus to build more confident assessments. Understand the SARs behind predictions from scientific comments within Derek Nexus – which describe the mechanism of action – and follow up on the knowledge to gather key supporting pieces of evidence within the supporting references.
Using Kaptis, Effiris and Derek Nexus within your drug discovery phase can enhance regulatory submissions through the provision of more comprehensive safety assessments.
What is an AOP?
An approach to documenting causal relationships between biological processes which lead to adverse outcomes/toxicity. AOPs start with a molecular initiating event (MIE) and through additional key events (KEs), lead to an adverse outcome (AO). Each sequential KE (including the MIE and AO) are connected to each other through key event relationships (KERs). Each KE should be measurable and therefore can be linked to a relevant assay. This framework enables data to be contextualised and organised in an intuitive way, to support decisions with respect to chemical safety assessments.
Have you read our collaborative paper, published with the National Institute of Health Sciences (NIHS) of Japan? The paper is based on …
We are delighted to announce that our paper ‘Using adverse outcome pathways to contextualise (Q)SAR predictions for reproductive toxicity – A case …